皮肤性病诊疗学杂志2023，Vol.30Issue(6)：539-543,5.DOI:10.3969/j.issn.1674-8468.2023.06.010
免疫检查点抑制剂和肿瘤靶向药物相关的皮肤不良反应:附22例报告
Clinical analysis of 22 cases of cutaneous adverse reactions caused by molecular targeted antitumor agents and immune checkpoint inhibitors
摘要
Abstract
Objective To analyze cutaneous adverse reactions induced by immune checkpoint inhibitors and targeted antitumor drugs.Methods We retrospectively analyzed the clinical data of 22 cases of cutaneous adverse reactions caused by molecular targeted antitumor agents and immune checkpoint inhibitors.Results The time between the occurrence of skin adverse reactions and the first use of targeted drugs or ICIs ranged from 1 day to 4 years,with an average of 7 months.Inpa-tients with CTCAE grades 3 and 4 accounted for 90.91％and 9.09％,respectively.Majority of CTCAE-grade 3 patients(90.00％)mainly presented with erythema and papules,and 15.00％of patients had mucous involvement.Two CTCAE-grade 4 patients were diagnosed with drug-induced bullosa epidermolysis,accompanied by elevated inflammatory markers and abnormal liver func-tion.The pathological findings of 8 patients with bullous pemphigoid,psoriasis or perforating col-lagen disease were similar to those of idiopathic diseases.All patients were discharged from hospi-tal following the treatments with anti-allergy,anti-inflammatory and intravenous immunoglobulin therapy.Conclusions The cutaneous adverse reactions induced by immune checkpoint inhibitors and targeted drugs are mainly CTCAE grades 3 and 4 in inpatients,exhibiting various manifesta-tions.Glucocorticoids and conventional treatments are effective.It is crucial to early diagnose and treat the skin adverse reactions.So far there is no good method to predict the development of drug adverse reactions.关键词
靶向药物/免疫检查点抑制剂/皮肤不良反应Key words
targeted drug/immune checkpoint inhibitors/dermal adverse reaction引用本文复制引用
木葵,周星雨,李亚萍..免疫检查点抑制剂和肿瘤靶向药物相关的皮肤不良反应:附22例报告[J].皮肤性病诊疗学杂志,2023,30(6):539-543,5.基金项目
国家自然科学基金面上项目(81472881) （81472881）
长沙市自然科学基金(kq2208323) （kq2208323）
